A Phase 1, Open-Label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2010
At a glance
- Drugs TRC 093 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 07 Jun 2010 Final results presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).
- 09 Feb 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 09 Feb 2010 Actual patient number (19) added as reported by ClinicalTrials.gov.